Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy

Yuchen Xu,Rui Song,Wenjuan Chen,Katie Strong,Daniel Shrey,Satyanarayana Gedela,Stephen F. Traynelis,Guojun Zhang,Hongjie Yuan
DOI: https://doi.org/10.1002/acn3.51406
IF: 5.43
2021-07-01
Annals of Clinical and Translational Neurology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>Genetic variants in the <i>GRIN</i> genes that encode N-methyl-D-aspartate receptor (NMDAR) subunits have been identified in various neurodevelopmental disorders, including epilepsy. We identified a <i>GRIN1</i> variant from an individual with early-onset epileptic encephalopathy, evaluated functional changes to NMDAR properties caused by the variant, and screened FDA-approved therapeutic compounds as potential treatments for the patient. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Whole exome sequencing identified a missense variant in <i>GRIN1</i>. Electrophysiological recordings were made from <i>Xenopus</i> oocytes and transfected HEK cells to determine the NMDAR biophysical properties as well as the sensitivity to agonists and FDA-approved drugs that inhibit NMDARs. A beta-lactamase reporter assay in transfected HEK cells evaluated the effects of the variant on the NMDAR surface expression. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>A recurrent de novo missense variant in <i>GRIN1</i> (c.1923G&gt;A, p.Met641Ile), which encodes the GluN1 subunit, was identified in a pediatric patient with drug-resistant seizures and early-onset epileptic encephalopathy. In vitro analysis indicates that GluN1-M641I containing NMDARs showed enhanced agonist potency and reduced Mg<sup>2+</sup> block, which may be associated with the patient's phenotype. Results from screening FDA-approved drugs suggested that GluN1-M641I containing NMDARs are more sensitive to the NMDAR channel blockers memantine, ketamine, and dextromethorphan compared to the wild-type receptors. The addition of memantine to the seizure treatment regimen significantly reduced the patient's seizure burden. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Interpretation</h3><p>Our finding contributes to the understanding of the phenotype–genotype correlations of patients with <i>GRIN1</i> gene variants, provides a molecular mechanism underlying the actions of this variant, and explores therapeutic strategies for treating <i>GRIN1</i>-related neurological conditions. </p></section>
neurosciences,clinical neurology
What problem does this paper attempt to address?